Turkish Competition Board initiated an investigation on 13 June 2019 on Novartis (Novartis Sağlık Gıda ve Tarım Ürünleri San. ve Tic. A.Ş.) and Roche (Roche Müstahzarları San. A.Ş.) following a preliminary inquiry based on allegations that they had infringed Article 4 of the Competition Act No. 4054 prohibiting anti-competitive agreements in order to ensure common use of Lucentis instead of cheaper medicines named Altuzan and Lucentis used for the treatment of eye diseases. The press release dated 3.7.2019 about the investigation, initiated by the decision numbered 19-21/307-M, is available via https://www.rekabet.gov.tr/tr/Guncel/novartis-saglik-gida-ve-tarim-urunleri-s-4e3f6b555e9de91180fd00505694b4c6